US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans to seek approval for the drug as it fights for market dominance with rival Novo Nordisk.
美国制药集团礼来(Eli Lilly)宣布，其最新一轮减肥药物试验已达到减重目标，这将推动其寻求该药物的批准，同时在与竞争对手诺和诺德(Novo Nordisk)的市场霸主之争中占据优势。
您已阅读9%（325字），剩余91%（3391字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。